Prof. Avivit Peer, Rambam Health Care Campus, Israel
Prof. Peer provides an in-depth analysis of evolving treatment strategies for advanced urothelial carcinoma, discussing the clinical value of targeted therapy and immunotherapy combinations. She also highlights key design features of the KEYMAKER-U04 subgroup study and explores subsequent treatment options following progression on first-line therapy.
Watch the full interview for detailed expert insights.